JP2019508467A5 - - Google Patents

Download PDF

Info

Publication number
JP2019508467A5
JP2019508467A5 JP2018548744A JP2018548744A JP2019508467A5 JP 2019508467 A5 JP2019508467 A5 JP 2019508467A5 JP 2018548744 A JP2018548744 A JP 2018548744A JP 2018548744 A JP2018548744 A JP 2018548744A JP 2019508467 A5 JP2019508467 A5 JP 2019508467A5
Authority
JP
Japan
Prior art keywords
carbonitrile
cyano
dihydro
pyrrolo
isoindoline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018548744A
Other languages
English (en)
Japanese (ja)
Other versions
JP6959250B2 (ja
JP2019508467A (ja
Filing date
Publication date
Priority claimed from GBGB1604647.6A external-priority patent/GB201604647D0/en
Application filed filed Critical
Publication of JP2019508467A publication Critical patent/JP2019508467A/ja
Publication of JP2019508467A5 publication Critical patent/JP2019508467A5/ja
Application granted granted Critical
Publication of JP6959250B2 publication Critical patent/JP6959250B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018548744A 2016-03-18 2017-03-17 癌治療用の2−シアノイソインドリン誘導体 Active JP6959250B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1604647.6 2016-03-18
GBGB1604647.6A GB201604647D0 (en) 2016-03-18 2016-03-18 Novel compounds
PCT/GB2017/050763 WO2017158388A1 (en) 2016-03-18 2017-03-17 2-cyanoisoindoline derivatives for treating cancer

Publications (3)

Publication Number Publication Date
JP2019508467A JP2019508467A (ja) 2019-03-28
JP2019508467A5 true JP2019508467A5 (enExample) 2020-03-05
JP6959250B2 JP6959250B2 (ja) 2021-11-02

Family

ID=55968548

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018548744A Active JP6959250B2 (ja) 2016-03-18 2017-03-17 癌治療用の2−シアノイソインドリン誘導体

Country Status (7)

Country Link
US (1) US10683269B2 (enExample)
EP (1) EP3429994B1 (enExample)
JP (1) JP6959250B2 (enExample)
CN (1) CN108698992B (enExample)
GB (1) GB201604647D0 (enExample)
MA (1) MA43746A (enExample)
WO (1) WO2017158388A1 (enExample)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY188957A (en) 2015-03-30 2022-01-14 Mission Therapeutics Ltd 1-cyano-pyrrolidine compounds as usp30 inhibitors
US10669234B2 (en) 2015-07-14 2020-06-02 Mission Therapeutics Limited Cyanopyrrolidines as dub inhibitors for the treatment of cancer
GB201521109D0 (en) 2015-11-30 2016-01-13 Mission Therapeutics Ltd Novel compounds
GB201522267D0 (en) 2015-12-17 2016-02-03 Mission Therapeutics Ltd Novel compounds
GB201522768D0 (en) 2015-12-23 2016-02-03 Mission Therapeutics Ltd Novel compounds
GB201602854D0 (en) 2016-02-18 2016-04-06 Mission Therapeutics Ltd Novel compounds
GB201603779D0 (en) 2016-03-04 2016-04-20 Mission Therapeutics Ltd Novel compounds
GB201604638D0 (en) 2016-03-18 2016-05-04 Mission Therapeutics Ltd Novel compounds
WO2017163078A1 (en) 2016-03-24 2017-09-28 Mission Therapeutics Limited 1-cyano-pyrrolidine derivatives as dbu inhibitors
JP6959332B2 (ja) 2016-09-27 2021-11-02 ミッション セラピューティクス リミティド Usp30の阻害剤としての活性を有するシアノピロリジン誘導体
GB201616511D0 (en) 2016-09-29 2016-11-16 Mission Therapeutics Limited Novel compounds
GB201616627D0 (en) * 2016-09-30 2016-11-16 Mission Therapeutics Limited Novel compounds
TWI771327B (zh) 2016-10-05 2022-07-21 英商使命醫療公司 新穎化合物
GB201617758D0 (en) 2016-10-20 2016-12-07 Almac Discovery Limited Pharmaceutical compounds
SG11201908940UA (en) 2017-03-30 2019-10-30 Hoffmann La Roche Isoquinolines as inhibitors of hpk1
GB201708652D0 (en) 2017-05-31 2017-07-12 Mission Therapeutics Ltd Novel compounds and uses
CN110831936B (zh) 2017-06-20 2023-03-28 特殊治疗有限公司 具有dub抑制剂活性的取代氰基吡咯烷
SG11202001684PA (en) 2017-10-06 2020-03-30 Forma Therapeutics Inc Inhibiting ubiquitin specific peptidase 30
ES2988920T3 (es) 2018-05-17 2024-11-22 Forma Therapeutics Inc Compuestos bicíclicos fusionados útiles como inhibidores de la peptidasa 30 específica de ubiquitina
TW202019905A (zh) 2018-07-24 2020-06-01 瑞士商赫孚孟拉羅股份公司 異喹啉化合物及其用途
JP7434285B2 (ja) * 2018-08-14 2024-02-20 アムジエン・インコーポレーテツド N-シアノ-7-アザノルボルナン誘導体及びその使用
TW202024053A (zh) 2018-10-02 2020-07-01 美商建南德克公司 異喹啉化合物及其用途
US11612606B2 (en) 2018-10-03 2023-03-28 Genentech, Inc. 8-aminoisoquinoline compounds and uses thereof
PL3860989T3 (pl) 2018-10-05 2023-07-10 Forma Therapeutics, Inc. Sprzężone piroliny, które działają jako inhibitory proteazy 30 swoistej dla ubikwityny (usp30)
CN109321940A (zh) * 2018-11-30 2019-02-12 西南大学 一种酰胺的电化学氧化合成方法及其应用
CN120698983A (zh) 2018-12-20 2025-09-26 C4医药公司 靶向蛋白降解
WO2020139916A1 (en) * 2018-12-26 2020-07-02 Forma Therapeutics, Inc. Inhibiting ubiquitin specific peptidase 9x
GB201905371D0 (en) 2019-04-16 2019-05-29 Mission Therapeutics Ltd Novel compounds
GB201905375D0 (en) 2019-04-16 2019-05-29 Mission Therapeutics Ltd Novel compounds
WO2021032935A1 (en) * 2019-08-21 2021-02-25 Kalvista Pharmaceuticals Limited Enzyme inhibitors
GB201912674D0 (en) 2019-09-04 2019-10-16 Mission Therapeutics Ltd Novel compounds
CN112538083B (zh) * 2019-09-23 2023-04-28 华东师范大学 一类靶向bcl6的芳香环并五元芳杂环类小分子有机化合物及其衍生物及其应用
CN110804041B (zh) * 2019-09-25 2023-03-31 香港科技大学深圳研究院 抗肿瘤的吲哚类化合物的制备方法及吲哚类化合物和应用
WO2021058018A1 (en) * 2019-09-29 2021-04-01 Beigene, Ltd. Inhibitors of kras g12c
CN113135924B (zh) * 2020-01-19 2024-04-26 广东东阳光药业股份有限公司 嘧啶衍生物及其在药物中的应用
GB202001980D0 (en) 2020-02-13 2020-04-01 Almac Discovery Ltd Therapeutic mentods
BR112022020058A2 (pt) 2020-04-08 2022-11-22 Mission Therapeutics Ltd N-cianopirrolidinas com atividade como inibidores de usp30
BR112022020644A2 (pt) 2020-05-28 2022-12-06 Mission Therapeutics Ltd Derivados de n-(1-ciano-pirrolidin-3-il)-5-(3-(trifluorometil)fenil) oxazol-2-carboxamida e os correspondentes derivados de oxadiazol como inibidores de usp30 para o tratamento de disfunção mitocondrial
JP7796047B2 (ja) 2020-06-04 2026-01-08 ミッション セラピューティクス リミティド Usp30阻害剤としての活性を有するn-シアノピロリジン
DK4161929T3 (da) 2020-06-08 2025-08-18 Mission Therapeutics Ltd 1-(5-(2-cyanopyridin-4-yl)oxazol-2-carbonyl)-4-methylhexahydropyrrolo[3,4-b]pyrrol-5(1h)-carbonitril som usp30-hæmmer til anvendelse i behandling af mitokondriedysfunktion, cancer og fibrose
CN114053270B (zh) * 2020-08-05 2023-06-13 兰州大学第二医院 泛素结合酶e2t的小分子抑制剂
GB202016800D0 (en) 2020-10-22 2020-12-09 Mission Therapeutics Ltd Novel compounds
WO2022146755A1 (en) * 2020-12-29 2022-07-07 Merck Sharp & Dohme Corp. Amido-substituted pyridyl compounds and methods of use thereof for the treatment of herpesviruses
MX2024002554A (es) * 2021-08-30 2024-07-02 Remix Therapeutics Inc Compuestos y metodos para modular el empalme.
JP2024544660A (ja) 2021-12-01 2024-12-03 ミッション セラピューティクス リミティド Usp30阻害剤としての活性を有する置換n-シアノピロリジン
AU2022407047A1 (en) * 2021-12-08 2024-07-25 Kineta, Inc. Bicyclic heteroarenes and methods of their use
GB202200753D0 (en) 2022-01-21 2022-03-09 Almac Discovery Ltd Pharmaceutical compounds
WO2023150619A2 (en) * 2022-02-02 2023-08-10 The Katholieke Universiteit Leuven Tetrahydropyridopyrimidines and related analogs for inhibiting yap/taz-tead
AU2024350153A1 (en) * 2023-09-27 2026-04-30 Beyang Therapeutics Co., Ltd. Menin-mll interaction inhibitor and preparation method therefor, and application
GB202408928D0 (en) 2024-06-21 2024-08-07 Mission Therapeutics Ltd Novel compounds
GB202411060D0 (en) 2024-07-29 2024-09-11 Mission Therapeutics Ltd Novel compounds

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5360569A (en) 1993-11-12 1994-11-01 Lever Brothers Company, Division Of Conopco, Inc. Activation of bleach precursors with catalytic imine quaternary salts
WO2001077073A1 (en) 2000-04-06 2001-10-18 Merck Frosst Canada & Co. Cathepsin cysteine protease inhibitors
ES2266258T3 (es) * 2000-09-15 2007-03-01 Vertex Pharmaceuticals Incorporated Compuestos de pirazol utiles como inhibidores de proteina cinasas.
WO2002088079A2 (en) 2001-05-01 2002-11-07 Bristol-Myers Squibb Company Dual inhibitors of pde 7 and pde 4
US7105667B2 (en) 2001-05-01 2006-09-12 Bristol-Myers Squibb Co. Fused heterocyclic compounds and use thereof
US7521557B2 (en) 2005-05-20 2009-04-21 Bristol-Myers Squibb Company Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods
CA2651072A1 (en) 2006-05-01 2007-11-08 Pfizer Products Inc. Substituted 2-amino-fused heterocyclic compounds
WO2012040527A2 (en) * 2010-09-24 2012-03-29 The Regents Of The University Of Michigan Deubiquitinase inhibitors and methods for use of the same
CN103402997B (zh) 2011-02-25 2015-08-26 柳韩洋行 二氨基嘧啶衍生物及其制备方法
EP2565186A1 (en) 2011-09-02 2013-03-06 Hybrigenics S.A. Selective and reversible inhibitors of ubiquitin specific protease 7
CN103030634B (zh) 2011-09-30 2015-07-15 山东轩竹医药科技有限公司 含有并环的噁唑烷酮类抗菌素
EP2938610A2 (en) * 2012-12-28 2015-11-04 The U.S.A. as represented by the Secretary, Department of Health and Human Services Inhibitors of the usp1/uaf1 deubiquitinase complex and uses thereof
US20170137426A1 (en) 2014-03-28 2017-05-18 Changzhou Jiekai Pharmatech Co., Ltd. Heterocyclic compounds as axl inhibitors
LT3166925T (lt) 2014-07-08 2018-06-11 Viiv Healthcare Uk Limited Izoindolino dariniai, skirti panaudoti virusinės infekcijos gydymui
GB201416754D0 (en) 2014-09-23 2014-11-05 Mission Therapeutics Ltd Novel compounds
MY188957A (en) 2015-03-30 2022-01-14 Mission Therapeutics Ltd 1-cyano-pyrrolidine compounds as usp30 inhibitors
US10669234B2 (en) 2015-07-14 2020-06-02 Mission Therapeutics Limited Cyanopyrrolidines as dub inhibitors for the treatment of cancer
GB201521109D0 (en) 2015-11-30 2016-01-13 Mission Therapeutics Ltd Novel compounds
GB201522267D0 (en) 2015-12-17 2016-02-03 Mission Therapeutics Ltd Novel compounds
GB201522768D0 (en) 2015-12-23 2016-02-03 Mission Therapeutics Ltd Novel compounds
GB201602854D0 (en) 2016-02-18 2016-04-06 Mission Therapeutics Ltd Novel compounds
GB201603779D0 (en) 2016-03-04 2016-04-20 Mission Therapeutics Ltd Novel compounds
GB201604638D0 (en) 2016-03-18 2016-05-04 Mission Therapeutics Ltd Novel compounds
WO2017163078A1 (en) 2016-03-24 2017-09-28 Mission Therapeutics Limited 1-cyano-pyrrolidine derivatives as dbu inhibitors
JP6959332B2 (ja) 2016-09-27 2021-11-02 ミッション セラピューティクス リミティド Usp30の阻害剤としての活性を有するシアノピロリジン誘導体
GB201616511D0 (en) 2016-09-29 2016-11-16 Mission Therapeutics Limited Novel compounds
GB201616627D0 (en) 2016-09-30 2016-11-16 Mission Therapeutics Limited Novel compounds
TWI771327B (zh) 2016-10-05 2022-07-21 英商使命醫療公司 新穎化合物

Similar Documents

Publication Publication Date Title
US9206183B2 (en) Substituted pyrazolo[1,5-a]pyridines as JAK inhibitors
JP2019504009A5 (enExample)
JP2018524367A5 (enExample)
JP2021515033A5 (enExample)
HRP20250373T1 (hr) Inhibitori parp1
RU2017121044A (ru) Производные амидотиадиазола в качестве ингибиторов надфн-оксидазы
JP2019508462A5 (enExample)
JP2020521730A5 (enExample)
JP2016505529A5 (enExample)
RU2016102137A (ru) Первичные карбоксамиды в качестве ингибиторов bik
JP6413032B2 (ja) 新規dgat2阻害剤
JP2018510183A5 (enExample)
JP2017537948A5 (enExample)
JP2010510319A5 (enExample)
JP2019505595A5 (enExample)
JP2013519733A5 (enExample)
JP2017525757A5 (enExample)
WO2013017461A1 (en) Pyridin-2(1h)-one derivatives as jak inhibitors
JP2017510644A5 (enExample)
JP2022551973A5 (enExample)
CA2905841A1 (en) Quinazoline and naphthyridine derivatives useful in the treatment of fibrotic disorders
JP2016514711A5 (enExample)
JP2018536686A5 (enExample)
RU2014147191A (ru) Амидопроизводные как блокаторы ttx-s
RU2015116532A (ru) Ингибиторы тирозинкиназы syk